Firstly, for selective PARP-1 inhibitors, where it precisely fits in currently remains to be seen. But for the EIK1003 study, we had patients previously treated with current-generation PARP inhibitors, Olaparib, Rucaparib, Niraparib, and so forth. And some of these patients also responded to treatment. So this may represent another treatment opportunity for previously PARP inhibitor-treated patients...
Firstly, for selective PARP-1 inhibitors, where it precisely fits in currently remains to be seen. But for the EIK1003 study, we had patients previously treated with current-generation PARP inhibitors, Olaparib, Rucaparib, Niraparib, and so forth. And some of these patients also responded to treatment. So this may represent another treatment opportunity for previously PARP inhibitor-treated patients. Also, since the PARP-1 inhibitor here, IK-1003, actually is combinable with chemotherapy, in this case Paclitaxel, this opens a whole new avenue of potential treatment opportunities for patients where the PARP-1 inhibitor may be safely combined with Paclitaxel here, but down the road also other compounds, in particular platinum compounds for ovarian cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
